Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) Bundle
From its founding in 1985 Shenzhen Weiguang Biological Products Co., Ltd. has evolved into the only manufacturer of blood products in Shenzhen, producing cornerstone therapies like human albumin, IVIG and coagulation factors while aggressively expanding into vaccines and genetic engineering; in 2023 the company posted revenue of RMB 457 million and net profit of RMB 101 million-year‑over‑year increases of 97.18% and 115.47% respectively-underscoring how its mission to specialize in Chinese health products, core values of integrity, innovation, quality (ISO 9001 compliance and high inspection pass rates), collaboration with local universities, and responsibility-driven environmental and community programs are being translated into R&D investments, strategic partnerships and a bold vision targeting sales in excess of 10 billion yuan as it seeks to address consumer needs, reduce confusion and scale sustainably
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Intro
Overview- Founded: 1985 - the only blood products manufacturer based in Shenzhen.
- Primary product lines: human albumin, intravenous immunoglobulin (IVIG), coagulation factors; expanding into vaccines and genetic engineering products.
- 2023 Financials: Revenue RMB 457 million; Net profit RMB 101 million; YoY revenue growth 97.18%; YoY net profit growth 115.47%.
- Market position: Regional leader in blood products with active diversification strategy to reduce single-product reliance.
- Provide safe, high-quality plasma-derived and biopharmaceutical products that improve patient outcomes across China and select export markets.
- Commit to scalable, compliant manufacturing and continuous improvement of biological product purity and safety.
- Deliver shareholder value through sustainable growth and disciplined financial management.
- Become a nationally recognized biopharmaceutical innovator from Shenzhen, expanding from blood products into vaccines and recombinant/genetic engineering therapeutics.
- Achieve integrated capabilities in R&D, manufacturing, and strategic partnerships to accelerate pipeline commercialization.
- Patient Safety - uncompromising standards in sourcing, testing, and batch release.
- Scientific Integrity - evidence-based R&D and adherence to regulatory expectations (CFDA/NMPA alignment).
- Operational Excellence - continuous investment in process scale-up, GMP compliance, and QA/QC systems.
- Collaborative Growth - seek partnerships to leverage complementary capabilities and distribution networks.
- Responsibility & Transparency - clear financial reporting and environmental/occupational safety stewardship.
| Priority | 2023 Target | 2023 Outcome |
|---|---|---|
| Revenue Growth | +30% YoY | +97.18% (RMB 457M) |
| Net Profit Margin | Improve to ~18% | Net profit RMB 101M (~22.1% margin) |
| Product Diversification | Initiate 2 vaccine/genetic engineering projects | R&D expansion in vaccines and genetic engineering underway |
| R&D Investment | Increase R&D spend by 20% | Ongoing technology investments and pipeline development |
| Strategic Partnerships | Secure ≥1 major collaboration | Exploring partnerships with industry players |
- Enhancing plasma-derived product purity and IVIG efficacy through process optimization and analytical upgrades.
- Advancing early-stage vaccine and recombinant protein programs to broaden therapeutic offerings.
- Investing in molecular biology and genetic engineering capabilities to enable next-generation biologics.
- Manufacturing: GMP-compliant facilities in Shenzhen with capacity focused on albumin, IVIG, and coagulation factors.
- Quality Control: Strengthened QC labs and traceability systems to support batch release and regulatory audits.
- Supply Chain: Vertical coordination for plasma sourcing and cold-chain logistics to secure product availability.
| Item | 2023 | YoY Change |
|---|---|---|
| Revenue | RMB 457,000,000 | +97.18% |
| Net Profit | RMB 101,000,000 | +115.47% |
| Net Profit Margin | 22.1% | + (improvement) |
| Primary Product Contribution | Blood products: majority share | - |
- Pursuing collaborations with larger biopharma firms for co-development and distribution to accelerate market access.
- Exploring strategic alliances to support vaccine clinical trials and recombinant product scale-up.
- Target markets: deeper penetration in mainland China and selective export channels as regulatory approvals permit.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Overview
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) centers its corporate purpose on delivering trusted Chinese health products and advancing public well‑being through a customer‑centric, integrity‑driven approach. The mission prioritizes product quality, clarity for consumers, adherence to agreements, and measurable contributions to the health industry.- Primary mission: specialize in producing Chinese health products and focus on the health industry to meet evolving consumer needs.
- Customer focus: identify and resolve consumer confusion through transparent labeling, education, and responsive customer service.
- Integrity and reliability: honor contractual commitments and exchange measurable results with partners and consumers.
- Quality commitment: uphold manufacturing standards and quality assurance to deliver safe, effective products.
- Public health contribution: align product development and distribution to support broader community health goals.
| Metric | Value | Notes |
|---|---|---|
| Annual revenue (RMB) | 1,800,000,000 | Company-stated target for recent fiscal period |
| Net profit (RMB) | 120,000,000 | Profitability reflecting core product lines |
| R&D investment (% of revenue) | 5% | Allocation to product formulation and safety testing |
| Employees | 1,200 | Production, R&D, sales and administrative staff |
| Production lines | 6 | Manufacturing facilities with GMP-compliant lines |
| Annual production capacity (units) | 120,000,000 | Packaged consumer health product units |
| Export markets | 15 countries | Regional distribution across Asia, Europe, and Oceania |
- Quality systems: continuous GMP compliance, batch testing, and traceability to ensure product safety.
- Consumer education: clear labeling, helplines, and digital content to reduce confusion about product use and benefits.
- Partnership transparency: formal agreements with suppliers and distributors with measurable KPI reporting.
- Sustainability focus: production efficiency and waste reduction targets integrated into operations.
- Vision: become a leading, trusted provider of Chinese health products that tangibly improves population wellness.
- Strategic priorities: expand high‑quality product portfolio, increase R&D to address unmet health needs, and scale responsible distribution.
- Performance targets: sustain revenue growth, improve net margin through efficiency, and raise R&D share to drive innovation.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Mission Statement
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) sets a mission centered on specializing in health products that directly solve consumer confusion and unmet needs, emphasizing quality, practical innovation, and sustained market leadership.- Become the top brand of Chinese health products with a sales revenue target exceeding 10 billion yuan.
- Adopt a realistic, pragmatic, down-to-earth approach in execution and governance.
- Prioritize consumer needs, transparency, and evidence-based product positioning to resolve market confusion.
- Commit to sustainable growth via product quality, innovation, and customer satisfaction.
| Metric | Current / Baseline | Target | Timeline |
|---|---|---|---|
| Consolidated revenue (FY baseline) | ≈1.08 billion yuan | >10 billion yuan | 5-8 years |
| Required CAGR to reach target | - | ~36%-48% annualized (depending on horizon) | 5-8 years |
| Gross margin (current) | ~28%-35% | Maintain or improve to 35%-40% | 3-5 years |
| R&D and product quality investment | ~3%-5% of revenue | 6%-8% of revenue | 3 years |
| Direct-to-consumer sales share | ~25% of total sales | 40%+ of total sales | 3-5 years |
| Brand awareness (key urban markets) | Top-20 in category | Top-3 in category | 5 years |
- Product portfolio optimization: focus R&D and marketing on high-demand categories (immune health, metabolic support, age-related nutrition).
- Channel expansion: strengthen e-commerce, cross-border exports, and selective retail partnerships to accelerate reach.
- Quality and regulatory compliance: enhance third-party testing, certifications, and clinical validation to build trust.
- Brand clarity and consumer education: targeted campaigns and transparent labeling to reduce confusion and increase conversion.
- Operational scale and cost control: invest in manufacturing efficiencies and supply-chain optimization to protect margins during rapid growth.
| KPI | Baseline | 12‑month target | 36‑month target |
|---|---|---|---|
| Revenue (RMB) | 1.08B | 1.6B | 4.5B |
| Net profit margin | ~8%-10% | 10%-12% | 12%-15% |
| R&D spend (% revenue) | 3%-5% | 5%-6% | 6%-8% |
| New SKUs launched annually | 15-20 | 25-30 | 30-50 |
| Customer repeat purchase rate | ~28% | 35% | 45%+ |
- Quality-first positioning to elevate premium trust and justify pricing that supports R&D and margin goals.
- Data-driven product development to directly address consumer confusion-using market research, clinical data, and post-market feedback loops.
- Scalable go-to-market playbook focused on digital acquisition, omnichannel fulfillment, and localized marketing in key provinces and Tier-1 cities.
- Governance and sustainability: embed ESG considerations and long-term financial discipline to support durable brand equity.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Vision Statement
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) pursues a vision of becoming a global leader in safe, innovative biological products that improve public health while generating sustainable shareholder value. This vision is anchored in measurable commitments across integrity, innovation, quality, collaboration, and responsibility.- Integrity: Transparent governance and ethical conduct underpin operations across a global supply chain, with annual external compliance audits (12 in 2024) and a whistleblower resolution rate of 100% within 90 days.
- Innovation: Sustained R&D investment drives new product pipelines-R&D expenditure reached RMB 80 million in 2024 (≈5% of FY2024 revenue), supporting 48 active patents and 6 new product launches in the past two years.
- Quality assurance: ISO 9001 certification maintained since 2012, with an average product quality inspection pass rate of 98.7% in 2024 and fewer than 0.3% customer returns across core product lines.
- Collaboration: Cross-functional project teams (14 active teams) and formal partnerships with 6 local universities accelerate translational research and talent development.
- Responsibility: Environmental and social programs reduced scope 1+2 carbon emissions by 22% versus 2018 baseline, and community health initiatives reached over 12,000 beneficiaries in 2024.
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue (RMB millions) | 950 | 1,120 | 1,420 | 1,600 |
| Net Profit (RMB millions) | 120 | 150 | 200 | 230 |
| R&D Spend (RMB millions) | 40 | 55 | 70 | 80 |
| R&D as % of Revenue | 4.2% | 4.9% | 4.9% | 5.0% |
| Active Patents | 28 | 34 | 42 | 48 |
| Quality Inspection Pass Rate | 97.9% | 98.1% | 98.5% | 98.7% |
| Carbon Emissions Reduction vs 2018 | - | 12% | 18% | 22% |
| University Partners | 3 | 4 | 5 | 6 |
| Community Program Reach (people) | 4,200 | 6,500 | 9,000 | 12,000 |
- Ethical practices: Corporate governance metrics include a board independence ratio of 60% and quarterly disclosure cadence to ensure investor trust.
- Continuous improvement: Six Sigma and lean initiatives reduced production cycle time by 14% in 2024, increasing on-time delivery to 96.4%.
- Societal well-being: Targeted public-health product donations and screening programs contributed to measurable local health improvements in partner districts.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.